Franc Gay speaks exclively to VJHemOnc on Treatg myeloma and associated disorrs. Watch terviews and discsns wh Franc Gay here.
Contents:
- FRANC GAY | ASCO 2018 | UPDATE ON THE FORTE TRIAL ACRDG TO RISK STAT NDMM
- FRANC GAY
- FRANC GAY
- FRANC GAY
FRANC GAY | ASCO 2018 | UPDATE ON THE FORTE TRIAL ACRDG TO RISK STAT NDMM
Franc Gay summariz fdgs om the FORTE trial to pare rfilzomib bo wh eher len/x or cyclophosphami/x, NDMM patients * francesca gay multiple myeloma *
Franc Gay is Associate Profsor the Universy of Toro, Department of Molecular Btechnology and Health Scienc, and works as hematologist at the SSD Clil trials on-ematology and multiple myeloma, Divisn of Hematology, Azienda Ospedaliero-Universaria Ctà lla Salute e lla Scienza di Toro, Italy. Gay’s ma rearch foc on the diagnosis and the clil and experimental treatment of patients wh multiple myeloma and associated disorrs, particularly of newly diagnosed patients eligible for tologo stem-cell transplantatn. Franc Gay, MD,.
Franc Gay, Chiara Cerrato, Delia Rota Slabri, Moni Galli, Angelo Belotti, Elena Zamagni, Anton Ledda, Mariella Grasso, Emanuele Angelucci, Anna Mara Liberati, Patrizia Tosi, Franc Pisani, Stefano Spada, Ombretta Annibali, Anna Baraldi, Paola Omedé, Piero Galieni, Ra Rizzi, Norbert Psta, Sonia Ronni, Donatella Vcelli, Anna Maria Cao, Massimo Offidani, Anton Palumbo, Pellegro Mto, Michele Cavo, Mar Bocdoro; Carfilzomib-Lenalidomi-Dexamethasone (KRd) Inductn-Autologo Transplant (ASCT)-Krd Consolidatn Vs KRd 12 Cycl Vs Carfilzomib-Cyclophosphami-Dexamethasone (KCd) Inductn-ASCT-KCd Consolidatn: Analysis of the Randomized Forte Trial Newly Diagnosed Multiple Myeloma (NDMM). Ma R, Mto P, Rota-Slabri D, Paris L, Gamberi B, Palmas A, Aquo S, Fabriis P, Giuliani N, De Rosa L, Gozzetti A, Celli C, Bertami L, Capra A, Oddolo D, Vcelli ID, Ronni S, Pavone V, Psta N, Cea M, Froni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Bocdoro M, Gay F. Cavo M, Gay F, Beksac M, Pantani L, Petcci MT, Dimopoulos MA, Dozza L, van r Holt B, Zweegman S, Oliva S, van r Veln VHJ, Zamagni E, Palumbo GA, Patriar F, Montef V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockew A, Ballanti S, Offidani M, Vcelli ID, Zambello R, Liberati AM, Anrsen NF, Broijl A, Troia R, Pasrella A, Benevolo G, Lev MD, Bos G, Ludwig H, Aquo S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von m Borne PA, Carava di Torto T, Zanr T, Drisen C, Specchia G, Waage A, Gimsg P, Mellqvist UH, van Marwijk Kooy M, Mnema M, Mandigers C, Cao AM, Palmas A, Carvalho S, Spencer A, Bocdoro M, Sonneveld P.
FRANC GAY
* francesca gay multiple myeloma *
Gay F, Oliva S, Petcci MT, Conticello C, Catalano L, Corradi P, Sislchi A, Magarotto V, Pour L, Carella A, Malfano A, Petrò D, Evangelista A, Spada S, Psta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Puli S, Patriar F, Hajek R, Spencer A, Bocdoro M, Palumbo A.
Gay F, et al. Franc Gay is Associate Profsor the Univeristy of Toro, and works as hematologist at the Myeloma Un, Divisn of Hematology, Azienda Ospedaliero-Universaria Ctà lla Salute e lla Scienza di Toro, Italy.
FRANC GAY
Joseph, 2 Franc Gay, 1 Efstaths Kastris, 3 Maria Tera Petcci, 4 Jonathan L.
Gay et al. FigureDisclosurGay:Amgen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Takeda: Honoraria, Membership on an enty's Board of Directors or advisory mte; Bristol-Myers Squibb: Honoraria, Membership on an enty's Board of Directors or advisory mte; Roche: Membership on an enty's Board of Directors or advisory mte; GSK: Membership on an enty's Board of Directors or advisory mte; AbbVie: Membership on an enty's Board of Directors or advisory mte; Adaptive: Membership on an enty's Board of Directors or advisory mte; Seattle Geics: Membership on an enty's Board of Directors or advisory mte; Onpeptis: Membership on an enty's Board of Directors or advisory mte; Janssen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Celgene: Honoraria, Membership on an enty's Board of Directors or advisory mte. Franc Gay, MD, PhD, is currently an Associate Profsor of Hematology at the Myeloma Un the Divisn of Hematology at the Universy of Tur, Tur, Italy, havg prevly worked as a Hematologist at the Azienda Ospedaliera Ctà lla Salute e lla Scienza di Toro, Tur, Italy.
Dr Gay pleted her medil gree 2004 and her fellowship hematology 2008, both om the Universy of Tur. In 2014, Dr Gay obtaed a PhD Medice and Experimental Therapy and has been a member of the young European Myeloma Network (EMN) board sce s formatn 2019. Dr Gay’s rearch is foced on the treatment of multiple myeloma and s associated diseas.
FRANC GAY
Dr Gay has prevly worked on many cuttg-edge clil trials and is currently heavily volved rearch vtigatg prognostic factors, such as measurable ridual disease (MRD), multiple myeloma.
Palumbo A, Avet-Loise H, Oliva S, Lokhorst HM, Goldschmidt H, Rosol L, Richardson P, Caltagirone S, Lahuerta JJ, Fan T, Brghen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Mto P, Lonial S, Petcci MT, Orlowski RZ, Zamagni E, Man G, Dimopoulos MA, Durie BG, Anrson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, More P. Franc Gay, MD, PhD, discs the FORTE trial parg rfilzomib pl lenalidomi and xamethasone vers rfilzomib pl cyclophosphami and xamethasone newly diagnosed patients wh multiple myeloma.
Franc Gay, MD, PhD, associate profsor of onlogy and urology at Johns Hopks MediceFranc Gay, MD, PhDThe batn of rfilzomib (Kyprolis), lenalidomi (Revlimid), and xamethasone (KRd) may reprent a new standard of re for patients wh newly diagnosed multiple myeloma, cludg those wh high-risk disease, said Franc Gay, MD,, a hematologist the Myeloma Un, Divisn of Hematology, Azienda Ospedaliero Universaria Ctà lla Salute e lla Scienza, prented updated efficy rults om the FORTE trial at the 2018 European Hematology Associatn Congrs.